CRISPR could help doctors attack blood cancer without destroying healthy cells
Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant. In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells f
CRISPR-Edited Stem Cell Therapy
-
CRISPR Application: Researchers utilized CRISPR technology to remove the CD33 protein from donor stem cells.
-
Therapeutic Goal: The method aims to target aggressive blood cancers while preserving essential healthy blood cells.
-
Clinical Scope: A clinical trial involving 30 patients demonstrated that edited cells successfully engrafted.
-
Treatment Efficacy: The modified donor cells appear to provide a protective shield for healthy blood cells following transplantation.
Clinical & Hematology Impact
Patients with aggressive blood cancers may gain a treatment option that reduces damage to healthy cells.
The procedure potentially improves patient outcomes post-transplant by protecting essential cellular functions.
Clinical Research Progress
- Long-term efficacy results from the 30-patient trial
- Expansion of CRISPR-edited donor cell therapy protocols
CRISPR Therapy FAQs
What is the primary function of the edited CD33-negative stem cells? ▾
They are designed to survive cancer-targeting treatments that would otherwise destroy healthy stem cells.
How many patients were involved in the initial trial? ▾
The study utilized a cohort of 30 patients.
This dispatch has been curated by Press Glob under international press wire fair-use reporting standards. Access the original reporting directly below.